HoxA9, a gene belonging to the Homeobox family, is instrumental in the embryonic development process, playing a pivotal role in the patterning of the axial skeleton, limbs, and hematopoietic system. It functions as a transcription factor that guides the expression of genes critical for the development and differentiation of cells within these regions. The regulation of HoxA9 is essential for maintaining the delicate balance between stem cell proliferation and the differentiation necessary for the formation of diverse tissue types. In the context of hematopoiesis, HoxA9's expression is vital for the proper development and maintenance of hematopoietic stem cells (HSCs), influencing both their renewal capabilities and their progression into mature blood cells. The activity of HoxA9, therefore, underpins fundamental aspects of development and cellular differentiation, with its precise expression levels being crucial for normal physiological processes.
The activation of HoxA9 is regulated through a complex interplay of signaling pathways, transcription factors, and epigenetic mechanisms that ensure its expression is tightly controlled and contextually relevant. Activation at the transcriptional level can be mediated by upstream signaling pathways, such as those involving Wnt or Notch, which influence HoxA9 gene expression through the action of transcription factors that bind to its promoter region. Additionally, epigenetic modifications, including DNA methylation and histone acetylation, play a crucial role in modulating HoxA9's chromatin structure, thereby affecting its transcriptional activation. These modifications can either enhance or suppress HoxA9 expression, depending on the developmental context and the specific combination of epigenetic marks. The regulation of HoxA9 is further refined by post-transcriptional mechanisms, including microRNAs that can modulate its mRNA stability and translation, adding an additional layer of control over its activity. Together, these mechanisms ensure the appropriate spatial and temporal expression of HoxA9, which is essential for its role in guiding development and differentiation processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tazarotene | 118292-40-3 | sc-220193 | 10 mg | $103.00 | ||
A synthetic retinoid that activates retinoic acid receptors, potentially upregulating HOXA9 by enhancing transcription in cells undergoing differentiation. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
An activator of adenylate cyclase, increasing cAMP levels and thereby activating PKA. PKA can phosphorylate transcription factors like CREB, which may lead to increased expression of genes including HOXA9. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor known to cause hyperacetylation of histones, potentially leading to the activation of HOXA9 expression by changing chromatin accessibility. | ||||||
Purmorphamine | 483367-10-8 | sc-202785 sc-202785A | 1 mg 5 mg | $57.00 $184.00 | 18 | |
An agonist of the smoothened receptor that activates the Hedgehog signaling pathway, possibly resulting in the upregulation of HOXA9 as part of the pathway's target gene expression profile. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
A short-chain fatty acid that acts as a histone deacetylase inhibitor, potentially enhancing the transcription of genes, including HOXA9, by promoting a more open chromatin state. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
A DNA methyltransferase inhibitor that could lead to demethylation and reactivation of genes that positively regulate HOXA9. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
A well-known histone deacetylase inhibitor that can cause an open chromatin structure at gene loci, possibly leading to increased expression of HOXA9. | ||||||
GSK 525762A | 1260907-17-2 | sc-490339 sc-490339A sc-490339B sc-490339C sc-490339D | 5 mg 10 mg 50 mg 100 mg 1 g | $300.00 $540.00 $940.00 $1680.00 $5900.00 | ||
A BET bromodomain inhibitor that can displace BET proteins from acetylated histones, potentially leading to increased transcription of HOXA9 by altering chromatin conformation. | ||||||